KATP Antagonists for Preterm Infant Growth and Glucose Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Preterm and low birth weight infants face challenges with hyperglycemia and impaired growth, and current insulin therapy methods, particularly intravenous administration, are risky and ineffective due to peripheral hyperinsulinemia and poor bioavailability of oral insulin formulations.
Innovation Solution
Enteral administration of a potassium ATP channel antagonist, such as glibenclamide, stimulates endogenous insulin secretion to treat hyperglycemia and promote catch-up growth in preterm and small-for-gestational-age infants, avoiding the adverse effects of insulin infusions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If intravenous insulin therapy is administered to preterm infants, then blood glucose control is improved, but the risk of hypoglycemia and mortality increases
Solution Approach 1:
Instead of administering insulin directly (which causes peripheral hyperinsulinemia and hypoglycemia), the invention uses KATP channel antagonists to stimulate endogenous insulin secretion from pancreatic beta cells. This indirect approach through receptor antagonism reverses the conventional direct insulin administration strategy, achieving glucose control while avoiding the harmful effects of exogenous insulin.
Solution Approach 2:
The KATP channel antagonist acts as an intermediary substance that mediates between the need for glucose control and the risk of hypoglycemia. By blocking KATP channels, it triggers endogenous insulin release in a controlled manner, serving as a mediator that achieves the desired metabolic effect without the direct risks of insulin therapy.
2Ease of operation
If oral insulin formulations are administered to preterm infants, then the ease of administration is improved, but the bioavailability and effectiveness deteriorate
Solution Approach 1:
The invention changes the chemical parameter of the insulin delivery system by using KATP channel antagonists (sulfonylureas or meglitinides) instead of insulin itself. These compounds have oral bioavailability and are not degraded by digestive enzymes, fundamentally changing the delivery parameters to enable effective oral administration in preterm infants.
3Reliability
If KATP channel antagonist is administered enterally, then the safety is improved by avoiding hypoglycemia, but the device complexity increases
Solution Approach 1:
The KATP channel antagonist enables the infant's own pancreatic beta cells to serve the function of insulin secretion. By stimulating endogenous insulin release, the body's own regulatory system serves itself, eliminating the need for complex external insulin delivery systems and monitoring required by conventional insulin therapy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively manages hyperglycemia and supports growth in preterm infants by maintaining blood glucose levels and promoting growth without inducing hypoglycemia, offering a safer alternative to insulin therapy.
Implementation Method 1
Enteral administration of a potassium ATP channel antagonist, such as glibenclamide, stimulates endogenous insulin secretion
Data Source
AI summary
The present invention relates to pharmaceutical compositions comprising an ATP- sensitive potassium (K ATP) channel antagonist <e.g. sulfonylureas, meglitinides> and methods for treating hyperglycaemia and/or promoting growth a premature and/or small for gestational age infant.